![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC38A9 |
Gene summary for SLC38A9 |
![]() |
Gene information | Species | Human | Gene symbol | SLC38A9 | Gene ID | 153129 |
Gene name | solute carrier family 38 member 9 | |
Gene Alias | URLC11 | |
Cytomap | 5q11.2 | |
Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | Q8NBW4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153129 | SLC38A9 | CCI_2 | Human | Cervix | CC | 1.58e-06 | 6.48e-01 | 0.5249 |
153129 | SLC38A9 | CCI_3 | Human | Cervix | CC | 3.74e-11 | 6.38e-01 | 0.516 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![]() | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00011016 | Cervix | CC | response to acid chemical | 31/2311 | 135/18723 | 4.16e-04 | 4.22e-03 | 31 |
GO:00712292 | Cervix | CC | cellular response to acid chemical | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
GO:00712301 | Cervix | CC | cellular response to amino acid stimulus | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
GO:00432004 | Cervix | CC | response to amino acid | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC38A9 | SNV | Missense_Mutation | novel | c.850T>C | p.Trp284Arg | p.W284R | Q8NBW4 | protein_coding | tolerated(0.23) | probably_damaging(0.964) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | novel | c.25A>G | p.Arg9Gly | p.R9G | Q8NBW4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.045) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | novel | c.732A>G | p.Ile244Met | p.I244M | Q8NBW4 | protein_coding | tolerated(0.16) | benign(0.077) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SLC38A9 | SNV | Missense_Mutation | c.451A>G | p.Met151Val | p.M151V | Q8NBW4 | protein_coding | tolerated(0.22) | benign(0) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
SLC38A9 | SNV | Missense_Mutation | novel | c.693N>G | p.Ile231Met | p.I231M | Q8NBW4 | protein_coding | tolerated(0.09) | benign(0.343) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | novel | c.320N>G | p.Leu107Arg | p.L107R | Q8NBW4 | protein_coding | tolerated(0.14) | benign(0.277) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | novel | c.133N>G | p.Thr45Ala | p.T45A | Q8NBW4 | protein_coding | tolerated(0.33) | benign(0.15) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | novel | c.1450N>A | p.Leu484Ile | p.L484I | Q8NBW4 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SLC38A9 | SNV | Missense_Mutation | novel | c.1216N>G | p.Tyr406Asp | p.Y406D | Q8NBW4 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SLC38A9 | SNV | Missense_Mutation | novel | c.941N>G | p.Phe314Cys | p.F314C | Q8NBW4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |